Latest Articlesddd
Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE …
Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter …
On March 27, we wrote about how positive results of Neurocrine Biosciences (NBIX) drug Ingrezza on …
CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the …
The FDA Approves Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis …
CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay …
Agenus (AGEN) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of …
Positive Results of INGREZZA on Tardive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists The results …
Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), …
AMGEN Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against …
Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller …
OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests …
Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX …
Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic …
Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS), announced positive results from the pivotal …
A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg …
An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for …
We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the …
Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of …
Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania. …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
